Tumor Necrosis Factor-
Female
Humans
Carcinogenesis
/ metabolism
Cell Transformation, Neoplastic
/ metabolism
Endothelial Cells
/ metabolism
Lymphangiogenesis
Lymphatic Metastasis
/ pathology
MAP Kinase Signaling System
Proto-Oncogene Proteins c-akt
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
Uterine Cervical Neoplasms
/ metabolism
Vascular Endothelial Growth Factor A
/ metabolism
Vascular Endothelial Growth Factor C
/ metabolism
Vascular Endothelial Growth Factors
/ metabolism
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
11
2022
revised:
14
01
2023
accepted:
31
03
2023
medline:
2
5
2023
pubmed:
1
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
Lymphatic metastasis is a common phenomenon of cervical cancer. Tumor necrosis factor- In this study, cervical cancer cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with or without TNF- We found that TNF- Collectively, TNF-
Sections du résumé
Background
UNASSIGNED
Lymphatic metastasis is a common phenomenon of cervical cancer. Tumor necrosis factor-
Methods
UNASSIGNED
In this study, cervical cancer cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with or without TNF-
Results
UNASSIGNED
We found that TNF-
Conclusion
UNASSIGNED
Collectively, TNF-
Identifiants
pubmed: 37124061
doi: 10.1155/2023/5679966
pmc: PMC10147529
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Tumor Necrosis Factor-alpha
0
Vascular Endothelial Growth Factor A
0
Vascular Endothelial Growth Factor C
0
Vascular Endothelial Growth Factors
0
VEGFA protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5679966Informations de copyright
Copyright © 2023 Xiao Chen et al.
Déclaration de conflit d'intérêts
These authors declared no competing interests in this research.
Références
Oncol Res Treat. 2016;39(9):516-20
pubmed: 27614991
Mol Ther. 2022 Jul 6;30(7):2522-2536
pubmed: 35440418
Anticancer Agents Med Chem. 2011 Jan;11(1):4-18
pubmed: 21269254
Onco Targets Ther. 2018 May 16;11:2875-2890
pubmed: 29844685
J BUON. 2016 Mar-Apr;21(2):320-5
pubmed: 27273940
Life Sci. 2017 Feb 1;170:56-63
pubmed: 27919820
Biosci Rep. 2020 Oct 30;40(10):
pubmed: 33034616
Bioengineered. 2022 Jan;13(1):61-70
pubmed: 34939526
Anticancer Drugs. 2020 Nov;31(10):1004-1011
pubmed: 32701561
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Cells. 2019 Jun 21;8(6):
pubmed: 31234354
Int Immunopharmacol. 2021 Jul;96:107580
pubmed: 33823430
Proc Nutr Soc. 2001 Aug;60(3):349-56
pubmed: 11681809
Expert Rev Mol Med. 2015 Jan 30;17:e3
pubmed: 25634527
FASEB J. 2021 Jan;35(1):e21181
pubmed: 33231340
Curr Probl Cancer. 2018 Sep;42(5):457-465
pubmed: 30064936
Altern Ther Health Med. 2023 Mar;29(2):64-69
pubmed: 36580668
Curr Probl Cancer. 2018 Mar - Apr;42(2):120-128
pubmed: 29530393
Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F107-F116
pubmed: 31736350
Saudi Med J. 2017 Mar;38(3):237-244
pubmed: 28251217
J Clin Oncol. 2016 Dec 10;34(35):4270-4276
pubmed: 27903155
Bioengineered. 2021 Dec;12(1):1555-1575
pubmed: 33955820
Nat Neurosci. 2020 Jul;23(7):842-853
pubmed: 32424282
Cell Death Dis. 2020 Aug 11;11(8):687
pubmed: 32826853
Bioengineered. 2021 Dec;12(1):7079-7092
pubmed: 34551673
Am J Physiol Regul Integr Comp Physiol. 2006 Oct;291(4):R880-4
pubmed: 16728464
Cancer Lett. 2019 Jun 28;452:1-13
pubmed: 30905820
Biochem Biophys Res Commun. 2018 Oct 20;505(1):309-316
pubmed: 30249397
PLoS One. 2013;8(2):e56664
pubmed: 23431386
Cancers (Basel). 2019 Aug 06;11(8):
pubmed: 31390756
Cancer Sci. 2020 Jul;111(7):2385-2399
pubmed: 32385953
Oncogene. 2019 Feb;38(8):1256-1268
pubmed: 30254211
Acta Pharmacol Sin. 2022 Oct;43(10):2666-2677
pubmed: 35228654
Anticancer Res. 2011 May;31(5):1757-64
pubmed: 21617236
Bioengineered. 2022 Apr;13(4):9060-9070
pubmed: 35301927
Int J Clin Exp Pathol. 2019 Jul 01;12(7):2474-2484
pubmed: 31934074
Oncol Rep. 2017 Mar;37(3):1477-1486
pubmed: 28098890
Cell Oncol (Dordr). 2020 Feb;43(1):1-18
pubmed: 31900901
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
Mol Med Rep. 2017 Aug;16(2):2075-2088
pubmed: 28656315
Bioengineered. 2021 Dec;12(1):4536-4545
pubmed: 34323178
Cancer Biother Radiopharm. 2022 Nov;37(9):779-791
pubmed: 33784470
Bioengineered. 2022 Feb;13(2):4610-4620
pubmed: 35156510
Oncogene. 2016 Oct 13;35(41):5337-5349
pubmed: 26923327
BMC Cancer. 2010 Apr 29;10:170
pubmed: 20429915
Fukushima J Med Sci. 2016 Jun 8;62(1):57-63
pubmed: 27210308
J Exp Clin Cancer Res. 2017 Feb 7;36(1):27
pubmed: 28173828
Int J Mol Sci. 2022 Dec 16;23(24):
pubmed: 36555705
World J Gastroenterol. 2011 Jul 14;17(26):3092-100
pubmed: 21912451
Medicina (Firenze). 1990 Oct-Dec;10(4):393-4
pubmed: 2099981
Cancer Res Treat. 2014 Jul;46(3):297-306
pubmed: 25038765
Curr Oncol Rep. 2018 Apr 2;20(5):40
pubmed: 29611060
Bioengineered. 2021 Dec;12(1):1916-1926
pubmed: 34002665
Cancer Biomark. 2021;30(3):287-298
pubmed: 33185588
Cancer Lett. 2015 Feb 28;357(2):438-47
pubmed: 25497008
Cancer Lett. 2021 Jan 28;497:154-164
pubmed: 33080310
Aliment Pharmacol Ther. 2019 Oct;50(7):822-823
pubmed: 31532545
Bioengineered. 2021 Dec;12(1):4374-4384
pubmed: 34304709
In Vivo. 2013 Nov-Dec;27(6):669-84
pubmed: 24292568
J Cell Physiol. 2021 Apr;236(4):2767-2781
pubmed: 33184870
Cancer Metastasis Rev. 2006 Dec;25(4):677-94
pubmed: 17160713
Cancer Lett. 2012 Jan 28;314(2):127-36
pubmed: 22071224
J Clin Invest. 2020 Jan 2;130(1):404-421
pubmed: 31593555
Bioengineered. 2021 Dec;12(1):1663-1675
pubmed: 33977869
Bioengineered. 2019 Dec;10(1):374-382
pubmed: 31431131
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2020 Mar;36(3):193-197
pubmed: 32389165
Prz Menopauzalny. 2015 Jun;14(2):112-7
pubmed: 26327898
Mol Med Rep. 2021 Jan;23(1):
pubmed: 33236135
Breast Cancer Res Treat. 2008 Dec;112(3):503-11
pubmed: 18165897
J Biol Chem. 2002 Aug 23;277(34):30622-8
pubmed: 12060665